Main Profile


Description in a few words:

The production of Koçak Farma is in line with cGMP Guidelines and WHO standards and the company has been certified by TÜV Rheinland with DIN EN ISO 9001:2000 ( Management of Quality System) and DIN EN ISO 14001:1999 (Management of Enviromental Systems) Certificate. Koçak Farma is the only company to have the 17025 Accreditation Of Quality Control And Calibration Laboratiories in Pharmaceutical sector.

Koçak Farma exports its products to more than 50 countries in five continents, including EU countries such as Germany, France, Italy and Spain from its facilities with EU GMP approval.

Current Leadership:

Dr. Hakan Koçak, CEO & General Manager

Founding Year:

Our focus on oncology since the 2000s has allowed us to supply one in every two products in Turkey today, and in 2005, we gained the right to sell in the EU. We produce in accordance with guidelines of cGMP and the WHO.


Number of machinery in Production and capacities: solid, liquid, sterile

Koçak Farma has the capability to manufacture almost all pharmaceutical forms including solids (Tablets, extended release tablets, capsules, soft gelatin capsules etc) liquids, semi solids, injectables (vials, ampoules, lyophilized vials and ampoules, cartridges, Prefilled Syringes, Disposable Pens, IV Solutions). The capacity of Çerkezköy facilities is 500 million unit/year. The capacity of IV Solution site is 150 million unit / year.

Main product categories or therapies of focus

Koçak Farma focuses in Oncology, Gynecology, Urology, Rheumatology, Infectious Diseases, Chest Diseases, Cardiology and General Health Protection

Number of APIs produced

Koçak Farma manufactures 10 APIs

Primary packaging production

Koçak Farma performs primary packaging for the products manufactured in its facilities.

Serialization Service

Koçak Farma performs serialization for the products manufactured in its facilities

Total number of delivered boxes/year

In Çerkezköy Facilities the company delivers around 300 million boxes/year and in Ayazağa IV Solution Facilities it delivers around 80 million units/year.


R&D focus

Koçak Farma develops Insulin Analogues, Monoclonal Antibodies (mAbs), bacterial, viral and recombinant vaccines as well as conventional small molecules in the Oncology space and other areas of focus. Around 100 scientists are working for new projects in its R&D center in Çerkezköy.


List of export countries:

Koçak Farma exports its products to more than 50 countries across five continents, including the majority of EU countries, CIS countries, Australia, African countries, South Korea and South American nations.

In More Depth

Number of employees

Koçak Farma has around 1,800 employees

GMP certificates

Koçak Farma has EU GMP certificates for oral solids and injectables for several production areas such as Oncology and Hormone Production areas.

Revenue or Growth Rate in past financial year

Koçak Farma has grown around 40% in recent years.

USP/ or a differentiating fact:

Koçak Farma is a leader in Biotechnology and Oncoloy in Turkey. Koçak Farma launched the first biosimilar product in the EU and Turkey, “Enoxaparin Sodium,” in Prefilled Syringe form in 2012 and has launched the first locally manufactured Insulin with Insulin Glargine API, “Glarin 1oo U/ml Solution for Injection in Pen for SC Use,” in 2017 in Turkey.

Prominent partnerships/ clients

Koçak Farma cooperates with many leading European companies for product development and marketing.